Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Harvard Bioscience ( (HBIO) ) just unveiled an update.
On September 5, 2025, Harvard Bioscience appointed Stephen DeNelsky to its Board of Directors, effective immediately, and he will also serve on the Nominating & Governance Committee. DeNelsky, a veteran in the life sciences industry with 30 years of experience, is expected to bring valuable expertise in financial strategy to the company, enhancing its governance and long-term value creation.
The most recent analyst rating on (HBIO) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Harvard Bioscience stock, see the HBIO Stock Forecast page.
Spark’s Take on HBIO Stock
According to Spark, TipRanks’ AI Analyst, HBIO is a Neutral.
Harvard Bioscience’s overall stock score reflects significant financial challenges, particularly in profitability and leverage, which weigh heavily on the score. While technical indicators and valuation metrics are not favorable, recent earnings call insights and corporate events provide some positive signals. The company’s strong cash flow growth and strategic leadership changes offer potential for recovery, but substantial risks remain.
To see Spark’s full report on HBIO stock, click here.
More about Harvard Bioscience
Harvard Bioscience, Inc. is a leading developer, manufacturer, and seller of technologies, products, and services that enable fundamental advances in life science applications, including research, drug and therapy discovery, bio-production, and preclinical testing for pharmaceutical and therapy development. The company serves a diverse range of customers, including academic institutions, government laboratories, and leading pharmaceutical, biotechnology, and contract research organizations, with operations in the United States, Europe, and China.
Average Trading Volume: 966,977
Technical Sentiment Signal: Sell
Current Market Cap: $21.29M
For an in-depth examination of HBIO stock, go to TipRanks’ Overview page.